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Abstract
Background/Objectives: Quercetin supplementation results in a variable plasma quercetin response in 
humans. The purpose of this study was to determine whether this variance is related to gender, age, body 
mass index (BMI), and other demographic and lifestyle factors.
Subjects/Methods: Subjects (N ¼ 1002, ages 18–85 years, 60% female and 40% male) were recruited from 
the community and randomized to one of three groups, with supplements administered using double-
blinded procedures: Q-500 (500 mg/day), Q-1000 (1000 mg/day), or placebo. Subjects ingested two soft 
chew supplements twice daily during the 12-week study. Fasting blood samples were obtained pre- and 
post-study, analyzed for plasma quercetin, and then compared between and within groups by gender, age 
group (o40, 40–59, and X60 years), BMI (o25, 25–29.9, and X30 kg/m2), self-reported physical fitness 
level, and diet intake (food group servings).
Results: Quercetin supplementation over 12 weeks caused a significant increase in overnight-fasted 
plasma quercetin, with a net increase of 332±21.0 and 516±30.8 mg/l for Q-500 and Q-1000 compared 
with 53.6±6.4 mg/l for placebo (interaction effect, Po0.001). The increase in plasma quercetin was highly 
variable within each quercetin supplementation group, but was unrelated to age, gender, BMI, fitness 
levels, or diet intake.
Conclusions: In summary, quercetin supplementation in doses of 500 and 1000 mg/day caused large but 
highly variable increases in plasma quercetin that were unrelated to demographic or lifestyle factors.
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Background/Objectives: Quercetin supplementation results in a variable plasma quercetin response in humans. The purpose of 
this study was to determine whether this variance is related to gender, age, body mass index (BMI), and other demographic and 
lifestyle factors. 
Subjects/Methods: Subjects (N ¼ 1002, ages 18–85 years, 60% female and 40% male) were recruited from the community and 
randomized to one of three groups, with supplements administered using double-blinded procedures: Q-500 (500 mg/day), 
Q-1000 (1000 mg/day), or placebo. Subjects ingested two soft chew supplements twice daily during the 12-week study. Fasting 
blood samples were obtained pre- and post-study, analyzed for plasma quercetin, and then compared between and within 
groups by gender, age group (o40, 40–59, and X60 years), BMI (o25, 25–29.9, and X30 kg/m2), self-reported physical 
fitness level, and diet intake (food group servings). 
Results: Quercetin supplementation over 12 weeks caused a significant increase in overnight-fasted plasma quercetin, with a net 
increase of 332±21.0 and 516±30.8 mg/l for Q-500 and Q-1000 compared with 53.6±6.4 mg/l for placebo (interaction effect,
Po0.001). The increase in plasma quercetin was highly variable within each quercetin supplementation group, but was 
unrelated to age, gender, BMI, fitness levels, or diet intake. 
Conclusions: In summary, quercetin supplementation in doses of 500 and 1000 mg/day caused large but highly variable 
increases in plasma quercetin that were unrelated to demographic or lifestyle factors. 
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Introduction 
In vitro, animal and epidemiologic studies support multiple 
bioactive effects for quercetin (3,30,40,5,7-pentahydroxy- 
flavone), including anti-oxidative (Hanasaki et al., 1994), 
anti-inflammatory (Read, 1995), anti-fibrogenic (Lee et al., 
2003), anti-hypertensive (Duarte et al., 2001), anti-patho- 
genic (Gulati et al., 2006), and cardioprotective benefits 
(Boots et al., 2008a). The in vivo health benefit of quercetin 
seems limited, however, because of low bioavailability and 
extensive metabolic transformation (Boyle et al., 2000; Lotito 
and Frei, 2006; Loke et al., 2008; Boots et al., 2008b). 
Quercetin  and  its  methylated  derivatives  (isorhamnetin, 
tamarixetin) are not present in aglycone form in human 
blood because of extensive glucuronide and sulfate conjuga- 
tion processes (Manach et al., 1998; Loke et al., 2008). The 
few available studies in humans show little if any quercetin 
supplementation-related decrease in oxidative stress and 
inflammation, a finding that is in contrast to in vitro and 
animal-based experiments (Boyle et al., 2000; Lotito and 
Frei, 2006; Egert et al., 2008). 
Human subjects can absorb significant amounts of 
quercetin from food or supplements, and elimination is 
quite slow, with a reported half-life ranging from 11 to 28 h 
(Manach et al., 1998; Erlund et al., 2000; Goldberg  et  al., 
2003; Egert et al., 2008). Long-term quercetin supplementa- 
tion, however, results in a highly variable plasma quercetin 
response, and little is known regarding the factors that 
explain this variance (Conquer et al., 1998; Erlund et  al., 
2000; Goldberg et al., 2003; Egert et al., 2008). In four 
different  human  trials,  quercetin  supplementation  with 
 
 
doses of 8–1000 mg/day for 2–6 weeks resulted in overnight- 
fasted plasma quercetin values with an unexpectedly wide 
inter-individual variation (Conquer et al., 1998; Erlund et al., 
2000; Edwards et al., 2007; Egert et al., 2008). Edwards et al., 
for example, reported a 13-fold range in overnight-fasted 
plasma quercetin for two-thirds of 41 subjects after 4 weeks 
of supplementation with 730 mg quercetin per day. Egert 
et al. have speculated that the variation in plasma quercetin 
response to quercetin supplementation may be explained by 
differences in absorption rates because of polymorphisms 
for intestinal enzymes and transporters. Support for this 
hypothesis  comes  from  Hollman’s  study  (Hollman  et  al., 
1995) of ileostomy subjects, in which a single dose of 100 mg 
quercetin had a measured absorption rate of 24±9% 
(mean±s.d.) with urine accumulation rates for quercetin that 
varied more than ninefold. 
We hypothesize that the variance in plasma quercetin 
response to long-term supplementation may be related at 
least in part to basic demographic and lifestyle factors. The 
primary objective of this study was to examine the influence 
of multiple factors including age, gender, body mass index 
(BMI), physical fitness level, chronic disease status, and 
habitual diet intake on plasma quercetin responses to 12-
weeks supplementation with 500 or 1000 mg quercetin 
per day in a large and disparate group of community- 
dwelling adults. 
 
 
Materials and methods 
 
Subjects 
Subjects (N ¼ 1023), 18–85 years of age, were recruited 
through mass advertising from the community. Half of the 
subjects were studied during a 12-week period from January 
to April 2008, and the second half from August to November 
2008. Subjects had to be noninstitutionalized, and women 
were excluded if pregnant or lactating. No other exclusion 
criteria were used. During recruitment, subjects were strati- 
fied by gender (B40% male, 60% female), age (40% young 
adult 18–40 years of age, 40% middle-aged 41–59, and 20% 
60 and over), and BMI groups (33% normal 18.5–24.9, 33% 
overweight 25–29.9, and 33% obese X30 kg/m2) to ensure 
uniform representation of these various subgroups in 
placebo, Q-500, and Q-1000. Subjects agreed to avoid any 
other supplements containing quercetin; no other  restric- 
tions were placed on diet, supplement usage, or medications. 
This study was conducted according to the guidelines laid 
down in the Declaration of Helsinki and all procedures 
involving human subjects were approved by the institutional 
review board of Appalachian State University. Written 
informed consent was obtained from all subjects. 
 
 
Research design 
Subjects were randomized to one of three groups: Q-500 
(500 mg/d  quercetin),  Q-1000  (1000 mg/day  quercetin),  or 
placebo  (PL).  These  doses  were  based  on  earlier  animal 
studies (Davis et al., 2009) and human studies conducted by 
our research team (Nieman et al., 2007a, b, c, 2009). Supple- 
ments were administered using double-blinded procedures. 
Subjects ingested two soft chew supplements twice daily 
(on awakening, and between 1400 hours and the last meal of 
the day) during the 12-week study period. The duration of 
the study  period  (12  weeks)  was  based  on  our  desire  to 
measure plasma quercetin responses to supplementation over 
a longer period than earlier studied in humans (2–6 weeks). 
Quercetin  supplements  were  provided  by  Quercegen 
Pharma (Newton, MA, USA) and were soft, individually 
wrapped  chews  (5.3 g/piece)  that  contained  either  125  or 
250 mg   quercetin   aglycone,   125   or   250 mg   vitamin   C 
(ascorbic  acid  and  sodium  ascorbate),  5  or  10 mg  niacin, 
and 20 kcal of sugars in a carnauba wax, soy lecithin, corn 
starch,  glycerine,  and  palm  oil  base  colored  with  FD&C 
yellow 5 and 6. Data from Quercegen Pharma indicate that 
bioavailability   of   quercetin   is   enhanced   with   ascorbic 
acid and niacin (unpublished data). Thus, this study tested 
whether or not soft chews with or without the combination 
of quercetin, ascorbic acid, and niacin had an influence on 
the plasma quercetin responses. Thus, placebo supplements 
were  prepared  in  the  same  way  minus  the  quercetin, 
vitamin  C,  and  niacin.  Earlier  studies  performed  by  our 
laboratory used these supplement and placebo formulas, and 
this   choice   was   repeated   in   this   study   to   allow   for 
comparison  of  results  (Nieman  et  al.,  2007a, b, c,  2009). 
Subjects started supplementing after the first blood sample 
and continued for 12 weeks. 
Lifestyle habit information was obtained by subjects’ self- 
report through an Internet-based site (SurveyMonkey.com, 
Portland, OR, USA) 2 weeks before the first laboratory visit 
for the study. A food frequency questionnaire was used to 
obtain typical daily consumption of fruits, vegetables, and 
red meat. Subjects were asked ‘On average, how many 
servings ofy.do you eat per day?’ Serving size information 
was provided for each food group, and then subjects checked 
a box representing how many servings they consumed on an 
average day (Lee and Nieman, 2010). Self-reported physical 
fitness level was assessed on a 10-point Likert scale, with 
subjects asked to compare their level with other persons 
of the same age, with 1 corresponding to low fitness and 
10 to  high  fitness.  Subjects’  height  was  measured  with 
a stadiometer, and body mass determined using a Tanita 
scale (Tanita, Arlington Heights, IL, USA). Subjects 
completed a monthly electronic log to verify adherence to 
the supplementation regimen. If a subject indicated diffi- 
culty in adhering to the supplementation schedule, they 
were removed from the study. 
 
 
Blood sample 
Blood samples were drawn into heparin tubes after an 
overnight fast in the morning (7–9 a.m.) before and after the 
12-week supplementation period. A subgroup of 170 subjects 
 
 
had their blood drawn monthly after the starting point of 
supplementation. Blood was immediately centrifuged at 
4000 g at 4 1C and aliquots of plasma samples were snap 
frozen to store at -80 1C. 
 
 
Enzymatic hydrolysis 
Quercetin and its conjugates were measured as described 
earlier (Nieman et al., 2007a, b, c). To each 500 ml human 
plasma, 10% DL-dithiothreitol solution (10 ml) was added 
before the addition of 50 ml of  0.58 mol/l  acetic  acid. 
The mixture was then spiked with 10 ml of 0.356 mmol/l 
fisetin internal standard. To this, a mixture of 50 ml enzyme 
b-glucuronidase/arylsulfatase and crude extract from Helix 
pomatia (Roche Diagnostics Corporation, Indianapolis, IN, 
USA) was added. The mixture was incubated for 2 h at 37 1C. 
Then 500 ml of 0.01 mol/l oxalic  acid  was  added  to  stop 
the enzymatic reactions. The microplate  was  vortexed 
for another 1 min before centrifugation  at  3000  r.p.m. 
for 17 min (Allegra X-22R centrifuge; Beckman Coulter, 
Fullerton, CA, USA). 
 
 
 
Solid phase extraction 
Waters (Milford, MA, USA) Oasis HLB 96-well sample 
extraction  plates  (30 mg,  30 mm)  were  conditioned  with 
1.0 ml methanol, 0.5 ml 0.01 mol/l  oxalic  acid,  and  1.0 ml 
DI water sequentially. The waste was pulled through at a 
speed of o0.2 ml/min. The supernatant of the enzyme 
hydrolysis mixture was then loaded in the extraction plate, 
and the samples were washed with 1.0 ml of 5% methanol in 
0.5 mol/l phosphoric acid and 1.0 ml of 50% methanol in 
0.5 mol/l phosphoric acid solution, respectively. Finally, 
samples were eluted with two volumes of 0.5 ml methanol 
and the eluents were combined into a clean microplate with 
elution flow rate kept at o0.2 ml/min. A total of 10% DL-
dithiothreitol solution (10 ml) was added before solvent 
evaporation at 30 1C with N2 blowing through. The dried 
samples were reconstituted into 50/50 methanol/water for 
HPLC analysis. 
 
 
 
HPLC-PDA analysis 
Chromatographic analysis was performed using the Ultimate 
3000 HPLC-PDA system (Dionex Corporation, Sunnyvale, 
CA, USA) using a Gemini C18 column (150 x 4.6 mm, 100A, 
5 mm) with Gemini C18 4 x 3.0 mm SecurityGuard cartridges 
(Phenomenex, Torrance, CA, USA). The column was kept at 
30 1C and the flow rate was 1.0 ml/min. Separation was 
carried out using a 15 min gradient of acetonitrile containing 
0.1% formic acid and water containing 0.1% formic acid. 
The PDA detector was set to monitor at 375 nm as well as 
scanning from 250 to 700 nm, and the injection volume was 
kept at 50 ml. 
Statistical procedures 
Data in Table 2 and Figure 2 were analyzed using a 3 (group) 
x 2 (time) repeated measures ANOVA, between groups 
design, with post hoc analysis using Bonferroni’s adjusted 
independent t-tests that contrasted pre- to post-supplementa- 
tion changes of Q-500 and Q-1000 with placebo (Po0.0125). 
2 presents these data by gender, BMI, and age groups. Data in 
Figure 1 were analyzed using a 3 (group) x 4 (time) repeated 
measures ANOVA. Data are expressed as means±s.e. We used 
a general linear model to predict change in plasma quercetin 
levels (Figure 3) (dependent factor) with all of the following 
independent  factors:  quercetin  intake  (placebo,  Q-500, 
and Q-1000 groups), gender (male, female), BMI, age, self-
reported physical  fitness  level,  cigarette  smoking habit, 
self-reported diet intake by food groups (tertiles of fruit, 
vegetable, and red meat food groups), and chronic disease 
status. Change in plasma quercetin was calculated by 
subtracting pre-supplementation from post-supplementa- 
tion levels, and then was log transformed to meet the 
normality assumption of the general linear model. 
 
 
 
Results 
 
Table 1 summarizes subject characteristics for each group. 
No significant group differences were found on age, weight, 
height, and BMI. For all subjects combined, 60% were female 
and 40% were male with a wide range in age and BMI. Of the 
1023 subjects recruited into the study, 1002 completed all 
phases of the study. Among the 21 dropouts (7 from the 
placebo group, 6 from Q-500, and 8 from Q-1000), 12 failed 
to take the supplement and/or adhere to testing procedures, 
and 9 reported adverse symptoms from taking the supple- 
ment. The adverse symptoms varied widely, and follow-up 
revealed no consistent pattern of symptoms that could be 
 
 
 
Figure 1 Overnight-fasted plasma quercetin concentration for 
subjects tested pre-study and monthly during the study. Values are 
mean±s.e. (mg/l). *Mean values were significantly different from 
that at pre-study (Po0.001). wMean values were significantly 
different from that of Q-500 (Po0.001). 
 
 
Table 1  Subject characteristics 
Variable  Gender Placebo Q-500 Q-1000 Total group 
N  335 334 333  1002 
Age        Males     43.8±1.5    45.3±1.2    45.5±1.4       46.0±0.5 
(years)    Females  47.4±1.1    47.2±1.1    45.2±1.1    (range 18–85) 
Weight   Males      84.8±1.4    85.7±1.2    88.1±1.5       77.2±0.6 
(kg)        Females  71.2±1.1    71.6±1.2    71.4±1.3     (42.7–157.5) 
Height    Males      1.77±0.06  1.78±0.04  1.77±0.06     1.70±0.03 
(m)         Females  1.64±0.05  1.65±0.05  1.64±0.04    (1.39–2.02) 
BMI        Males     27.0±0.4    26.9±0.4    28.1±0.4       26.7±0.2 
(kg/m2)  Females  26.4±0.4    26.2±0.4    26.4±0.5      (16.7–52.7) 
 
 
Abbreviation: BMI, body mass index. 
Values are mean±s.e. 
No statistical differences between groups were found for any of the variables. 
 
 
 
 
ascribed to taking the quercetin supplements. Thirty-seven 
percent of subjects reported past or current history for one or 
more chronic diseases: hypertension (19%), arthritis (16%), 
cancer (6%), cardiovascular disease (4%), diabetes (4%). Q-
1000, Q-500, and placebo groups did not differ when 
compared for physical fitness level, food group intake, or 
chronic disease status (data not shown). 
Plasma quercetin data before and after the 12-week 
study are shown in Table 2. As depicted in Figure 1, the 
dose–response effect occurred before the first month and 
was maintained through the rest of the study. Significant 
increases in plasma quercetin were measured for Q-500 and 
Q-1000 (group interaction factor Po0.001) (see Figure 2; 
Table 2). The increase in plasma quercetin for Q-1000 was 
also significantly greater than Q-500, indicating a dose– 
response effect. The increase in plasma quercetin for Q-500 
and Q-1000 compared with placebo did not differ when 
comparing gender, age groups, or BMI (Table 2). Figure 3 
compares scatter plots for the change in plasma quercetin in 
each group. Using the general linear model and P-value 
cutoff 0.05, we found that change in plasma quercetin levels 
was significantly predicted by quercetin intake (placebo, Q-
500, Q-1000 groups), but was not predicted by gender, 
age, BMI, chronic disease status, self-reported diet intake, 
smoking, and physical fitness levels. 
 
 
Discussion 
 
Quercetin supplementation over 12 weeks in this large and 
disparate group of community-dwelling adults caused a 
significant increase in overnight-fasted plasma quercetin 
concentration, with a percentage increase of 385 and 575% 
for Q-500 and Q-1000, respectively. Using data from a 
subgroup of our study population, the dose–response 
increase  in  plasma  quercetin  for  Q-500  and  Q-1000  was 
Table 2  Plasma quercetin concentration pre- and post-12-week study 
Variable Time Placebo Q-500 Q-1000 
N   333 332  329 
Quercetin (mg/l)  Pre-study 102±4.7     86.2±4.2 89.6±4.1 
Post-study   156±5.8 418±21.3*    605±30.6*w 
 
Gender 
Males, n 122 136 131 
Quercetin Pre-study 112±8.4     86.9±5.9 86.5±5.9 
(mg/l) Post-study   163±10.7   414±37.4*   655±57.5*w 
Females, n 211 195 199 
Quercetin Pre-study    96.8±5.5    85.3±5.8 91.7±5.6 
(mg/l) Post-study   152±6.9 418±25.0*    573±33.9*w 
 
Age (years) 
o40 years, n 112 107 121 
Quercetin Pre-study 118±9.0     86.0±8.0 86.1±6.5 
(mg/l) Post-study   160±10.7   433±36.1*   674±64.9*w 
40–59 years, n 140 141 145 
Quercetin Pre-study    91.7±6.4    84.7±6.0 94.6±6.2 
(mg/l) Post-study   150±8.6 394±26.4*    533±28.5*w 
60–85 years, n 81 84 64 
Quercetin Pre-study    98.5±9.3    89.1±8.2 85.2±34.4 
(mg/l) Post-study   161±11.9   439±55.0*   640±74.8*w 
 
BMI (kg/m2) 
o25,  n 152 157 138 
Quercetin Pre-study 105±6.6     88.7±6.3 105±6.8 
(mg/l) Post-study   153±8.5 439±33.8*    593±40.7*w 
25–29.9,  n 95 94 109 
Quercetin Pre-study 105±9.3     75.7±6.5 74.8±5.9 
(mg/l) Post-study   161±11.1   375±32.0*   611±59.6*w 
X30,  n 86 81 83 
Quercetin Pre-study    95.4±9.4    93.6±9.3 83.9±8.5 
(mg/l) Post-study   155±11.7   427±44.2*   617±65.1*w 
 
 
Abbreviation: BMI, body mass index. 
Values are mean±s.e. 
*Po0.001, significant change from pre-study compared with placebo. 
wPo0.001, significant change from pre-study compared with Q-500. 
 
 
achieved within the first month and maintained for the rest 
of the study. High inter-subject variation was unrelated to 
demographic or lifestyle factors, including age, gender, BMI, 
self-reported physical fitness levels, chronic disease status, or 
habitual dietary intake. 
Earlier quercetin supplementation studies in humans have 
also reported high inter-individual variation in the plasma 
quercetin response. These studies have had several design 
limitations including small subject numbers with widely 
varying dosing regimens, making it difficult to draw 
conclusions regarding the underlying causes for the wide 
variation in plasma quercetin response. Conquer et al. (1998) 
provided 13 healthy subjects with 1000 mg/day quercetin for 
28 days. Post-supplementation overnight-fasted plasma 
quercetin levels ranged between 0 and 899 mg/l for 95% of 
subjects, but no rationale was provided for this variation. 
Another human study (N ¼ 41) using quercetin aglycone 
supplements (730 mg quercetin/day for 28 days) (Edwards 
et  al.,  2007)  showed  that  post-supplementation  plasma 
quercetin   concentrations   (mean±s.d.)   for   the   placebo 
 
 
 
 
Figure 2 The  change in overnight-fasted plasma quercetin 
concentration pre- and post-study. Values are mean±s.e. (mg/l). 
*Mean value was significantly different from that of placebo 
(Po0.001). wMean value was significantly different from that of Q-
500   (Po0.001). 
 
 
 
Figure 3 Scatter plot in the change in overnight-fasted plasma 
quercetin concentration pre- and post-study. 
 
 
and treatment groups were 210±198 and 429±365 mg/l, 
respectively. The s.d. indicates a wide range of post- 
supplementation plasma quercetin concentrations. 
Egert et al. (2008) provided 35 healthy subjects with 50, 
100, or 150 mg quercetin/day for 2 weeks. A high inter- 
individual variation in the increase of plasma quercetin 
concentrations compared with baseline was reported 
within each of the three quercetin supplementation groups: 
64–370%,   117–1304%,   and   139–2343%   for   the   50,   100, 
and  150 mg/day  groups,  respectively.  In  a  subgroup  of 
15 subjects,  plasma  pharmacokinetic  responses  after 
oral intakes of 50, 100, or 150 mg quercetin varied widely, 
but no association was found with gender or body weight 
(mg quercetin per kilogram body weight) and tmax values. 
The variability in plasma quercetin concentrations was 
higher post-supplementation than at baseline. The authors 
speculated that some individuals may be better absorbers 
of oral quercetin supplements because of polymorphisms 
for intestinal  enzymes or transporters (Manach et al., 
2005; Egert et al., 2008). Egert et al. suggested that another 
factor explaining the variant plasma response to quercetin 
supplementation may include the composition of meals 
taken around the time of supplementation. Our data 
agrees that variation in plasma quercetin response with 
supplementation is unrelated to gender or BMI. 
Most recently,  a  group  of  93  overweight  subjects  with 
a high-cardiovascular  disease  risk  phenotype  completed 
a double-blinded, placebo-controlled, cross-over study. 
Subjects ingested 150 mg/day quercetin or placebo over 6-
week periods separated by a 5-week washout period 
(Egert et  al.,  2009).  High  inter-individual  variations 
were observed in plasma quercetin concentrations post- 
supplementation, with a range of 13–224 mg/l. This 
variation was unrelated to gender status, as confirmed in 
our study. 
Thus, using data from multiple studies including our own, 
human subjects can absorb about one-fourth of quercetin 
ingested from food or supplements, with a resulting plasma 
concentration that varies widely both acutely and chroni- 
cally (Erlund et al., 2000; Egert et al., 2008, 2009). The acute 
variation in individual dose–response curves after quercetin 
supplementation seems to increase in parallel with the 
amount ingested, as inferred by our data. According to 
Barnes (2008), solving  the  issue  of  inter-subject  variation 
in flavonoid bioavailability could involve a coordinated 
research design using the tools of genomics, transcriptomics, 
proteomics, and metabolomics. The discovery of specific 
alterations in single nucleotide polymorphisms in genes that 
interact with nutrients and other bioactive foods in humans 
may help explain differences in absorption, metabolism, and 
functional responses to flavonoid supplementation. 
We acknowledge several limitations in the design of our 
investigation. In particular, we relied on subject recall for 
lifestyle information including diet intake and physical 
fitness level. Subjects used a semi-quantitative food 
frequency questionnaire to indicate typical  daily  intake 
for three food groups (fruits, vegetables, and red meats). 
This approach is often used to divide groups into high, 
medium, and low intake, but does not provide information 
 
 
on  the  volume  of  specific  foods  or  intake  of  fats  and 
condiments that may influence quercetin absorption. As 
addressed in the Materials and methods section of this paper, 
unpublished animal data support the addition of vitamin C 
and niacin to quercetin supplements to enhance bioavail- 
ability. Thus, we tested the combination of quercetin, 
vitamin C, and niacin compared with a blank placebo on 
the plasma quercetin response, and the reader should keep 
this context in mind. 
In summary, a large group of  male and female adults 
varying widely in age and BMI ingested high amounts of 
quercetin or placebo for 12 weeks. As found in earlier studies, 
overnight-fasted plasma quercetin levels after supplementa- 
tion varied widely between subjects within each group. This 
variation was unrelated to age, gender, BMI, self-reported 
physical fitness levels, smoking habit, chronic disease status, 
or diet intake as assessed through a semi-quantitative, food 
frequency approach. These data support earlier results that 
the variable plasma quercetin response to supplementation 
is not associated with demographic or lifestyle factors, but to 
other unmeasured variables that may include differences in 
absorption rates  because of polymorphisms for intestinal 
enzymes and transporters. 
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